A large case–control analysis of 113 000 women via the Breast Cancer Association Consortium (BCAC)8 demonstrated similar levels of BC risk with an OR of 1.93 (95% CI 1.2 to 3.11) for RAD51C and 1.8 (95% CI 1.11 to 2.93) for RAD51D. Here, RAD51D is linked to breast carcinoma.